Characteristics of a <i>CCL21</i> Gene–Modified Dendritic Cell Vaccine Utilized for a Clinical Trial in Non–Small Cell Lung CancerMichael S. Oh, Bin Liu, Camelia Dumitras et al.|Molecular Cancer Therapeutics|2024Cited by 10
Abstract CT219: Phase I trial of <i>in situ</i> vaccination with autologous <i>CCL21</i> gene-modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced non-small cell lung cancer (NSCLC)Bin Liu, Steven M. Dubinett, Kanwarpal Kahlon et al.|Cancer Research|2022Cited by 1